Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plants

BMC Complementary and Alternative Medicine

Volumn 9, Issue , 2009, Pages

  Park, In Woo ^a   Han, Changri ^b   Song, Xiaoping ^b   Green, Linden A ^a   Wang, Ting ^a   Liu, Ying ^a   Cen, Changchun ^b   Song, Xinming ^b   Yang, Biao ^b   Chen, Guangying ^b   He, Johnny J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAINAN NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DIMETHYL SULFOXIDE; GLYCOPROTEIN GP 120; LUCIFERASE; PLANT EXTRACT; TRIGONOSTEMA XYPHOPHYLLOIDES EXTRACT; UNCLASSIFIED DRUG; VATICA ASTROTRICHA EXTRACT; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIPTEROCARPACEAE; DRUG CYTOTOXICITY; ENZYME ACTIVITY; EUPHORBIA; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LEUKEMIA CELL LINE; PLANT STEM; REPORTER GENE; REVERSE TRANSCRIPTION; TRIGONOSTEMA XYPHOPHYLLOIDES; VATICA ASTROTRICHA; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS INHIBITION; DRUG EFFECT; GIANT CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DIPTEROCARPACEAE; EUPHORBIACEAE; GIANT CELLS; HIV INFECTIONS; HIV-1; HUMANS; JURKAT CELLS; PLANT EXTRACTS; VIRUS REPLICATION;

EID: 69949121290     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-9-29     Document Type: Article

References (47)

1. Barre-Sinoussi F Chermann JC Rey F Nugeyre MT Chamaret S Gruest J Dauguet C Axler-Blin C Vezinet-Brun F Rouzioux C Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science 1983, 220:868-871. 10.1126/ science.6189183 6189183
2. Broder S Gallo RC A pathogenic retrovirus (HTLV-III) linked to AIDS N Engl J Med 1984, 311:1292-1297. 6208484
3. Deen KC McDougal JS Inacker R Folena-Wasserman G Arthos J Rosenberg J Maddon PJ Axel R Sweet RW A soluble form of CD4 (T4) protein inhibits AIDS virus infection Nature 1988, 331:82-84. 10.1038/331082a0 3257544
4. Eckert DM Kim PS Mechanisms of viral membrane fusion and its inhibition Annu Rev Biochem 2001, 70:777-810. 10.1146/annurev.biochem.70.1.777 11395423
5. Platt EJ Durnin JP Kabat D Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus J Virol 2005, 79:4347-4356. 10.1128/ JVI.79.7.4347-4356.2005 1061535 15767435
6. Ray N Doms RW HIV-1 coreceptors and their inhibitors Curr Top Microbiol Immunol 2006, 303:97-120. full_text 16570858
7. Coffin J Hiughes S Varmus H Retroviruses Plainview, NY, USA: Cold Spring Harbor Laboratory Press 1997.
8. Mitchell RS Beitzel BF Schroder AR Shinn P Chen H Berry CC Ecker JR Bushman FD Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences PLoS Biol 2004, 2:E234. 10.1371/ journal.pbio.0020234 509299 15314653
9. Scherdin U Rhodes K Breindl M Transcriptionally active genome regions are preferred targets for retrovirus integration J Virol 1990, 64:907-912. 249188 2296087
10. Schroder AR Shinn P Chen H Berry C Ecker JR Bushman F HIV-1 integration in the human genome favors active genes and local hotspots Cell 2002, 110:521-529. 10.1016/S0092-8674(02)00864-4 12202041
11. Bieniasz PD Late budding domains and host proteins in enveloped virus release Virology 2006, 344:55-63. 10.1016/j.virol.2005.09.044 16364736
12. Martin-Serrano J Zang T Bieniasz PD Role of ESCRT-I in retroviral budding J Virol 2003, 77:4794-4804. 10.1128/JVI.77.8.4794-4804.2003 152150 12663786
13. Zhu T Mo H Wang N Nam DS Cao Y Koup RA Ho DD Genotypic and phenotypic characterization of HIV-1 patients with primary infection Science 1993, 261:1179-1181. 10.1126/science.8356453 8356453
14. Hogg RS Heath KV Yip B Craib KJ O'Shaughnessy MV Schechter MT Montaner JS Improved survival among HIV-infected individuals following initiation of antiretroviral therapy JAMA 1998, 279:450-454. 10.1001/jama.279.6.450 9466638
15. Mocroft A Vella S Benfield TL Chiesi A Miller V Gargalianos P d'Arminio Monforte A Yust I Bruun JN Phillips AN Lundgren JD Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group Lancet 1998, 352:1725-1730. 10.1016/S0140-6736(98)03201-2 9848347
16. Palella FJ Jr Delaney KM Moorman AC Loveless MO Fuhrer J Satten GA Aschman DJ Holmberg SD Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 1998, 338:853-860. 10.1056/ NEJM199803263381301 9516219
17. Chou R Huffman LH Fu R Smits AK Korthuis PT Screening for HIV: A review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 2005, 143:55-73. 15998755
18. Hawkins T Appearance-related side effects of HIV-1 treatment AIDS Patient Care STDS 2006, 20:6-18. 10.1089/apc.2006.20.6 16426151
19. d'Arminio Monforte A Lepri AC Rezza G Pezzotti P Antinori A Phillips AN Angarano G Colangeli V De Luca A Ippolito G Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients Aids 2000, 14:499-507. 10.1097/00002030-200003310-00005 10780712
20. Fauci AS Johnston MI Dieffenbach CW Burton DR Hammer SM Hoxie JA Martin M Overbaugh J Watkins DI Mahmoud A Greene WC HIV vaccine research: The way forward Science 2008, 321:530-532. 10.1126/science.1161000 18653883
21. Mauck CK Straten AV Using Objective Markers to Assess Participant Behavior in HIV Prevention Trials of Vaginal Microbicides J Acquir Immune Defic Syndr 2008, 49:64-9. 10.1097/QAI.0b013e318183a917 18667920
22. Sekaly RP The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development? J Exp Med 2008, 205:7-12. 10.1084/ jem.20072681 2234358 18195078
23. Van Damme L Govinden R Mirembe FM Guedou F Solomon S Becker ML Pradeep BS Krishnan AK Alary M Pande B Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission N Engl J Med 2008, 359:463-472. 10.1056/NEJMoa0707957 18669425
24. Bjorndal A Deng H Jansson M Fiore JR Colognesi C Karlsson A Albert J Scarlatti G Littman DR Fenyo EM Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype J Virol 1997, 71:7478-7487. 192094 9311827
25. Li J Liu Y Park IW He JJ Expression of exogenous Sam68, the 68-kilodalton SRC-associated protein in mitosis, is able to alleviate impaired Rev function in astrocytes J Virol 2002, 76:4526-4535. 10.1128/ JVI.76.9.4526-4535.2002 155096 11932418
26. Liu Y Kim BO Kao C Jung C Dalton JT He JJ Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa, is a negative regulator of androgen receptor (AR) transcription activation J Biol Chem 2004, 279:21766-73. 10.1074/jbc.M314321200 15031286
27. He J Chen Y Farzan M Choe H Ohagen A Gartner S Busciglio J Yang X Hofmann W Newman W CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia Nature 1997, 385:645-649. 10.1038/385645a0 9024664
28. Li J Liu Y Kim BO He JJ Direct participation of Sam68, the 68-kilodalton Src-associated protein in mitosis, in the CRM1-mediated Rev nuclear export pathway J Virol 2002, 76:8374-8382. 10.1128/ JVI.76.16.8374-8382.2002 155124 12134041
29. Xiang YZ Shang HC Gao XM Zhang BL A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials Phytother Res 2008, 22:851-858. 10.1002/ ptr.2384 18567057
30. He J Landau NR Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor J Virol 1995, 69:4587-4592. 189211 7769729
31. Doranz BJ Rucker J Yi Y Smyth RJ Samson M Peiper SC Parmentier M Collman RG Doms RW A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors Cell 1996, 85:1149-1158. 10.1016/S0092-8674(00)81314-8 8674120
32. De Clercq E New developments in anti-HIV chemotherapy Biochim Biophys Acta 2002, 1587:258-275. 12084468
33. De Clercq E The design of drugs for HIV and HCV Nat Rev Drug Discov 2007, 6:1001-1018. 10.1038/nrd2424 18049474
34. Gore-Felton C Vosvick M Power R Koopman C Ashton E Bachmann MH Israelski D Spiegel D Alternative therapies: A common practice among men and women living with HIV J Assoc Nurses AIDS Care 2003, 14:17-27. 10.1177/ 1055329003014003002 12800809
35. Josephs JS Fleishman JA Gaist P Gebo KA Use of complementary and alternative medicines among a multistate, multisite cohort of people living with HIV/AIDS HIV Med 2007, 8:300-305. 10.1111/ j.1468-1293.2007.00474.x 17561876
36. De Clercq E Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection Med Res Rev 2000, 20:323-349. 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A 10934347
37. Gochfeld DJ El Sayed KA Yousaf M Hu JF Bartyzel P Dunbar DC Wilkins SP Zjawiony JK Schinazi RF Schlueter Wirtz S Marine natural products as lead anti-HIV agents Mini Rev Med Chem 2003, 3:401-424. 10.2174/ 1389557033487962 12769693
38. Tziveleka LA Vagias C Roussis V Natural products with anti-HIV activity from marine organisms Curr Top Med Chem 2003, 3:1512-1535. 10.2174/ 1568026033451790 14529524
39. Gustafson KR Sowder RC 2nd Henderson LE Cardellina JH 2nd McMahon JB Rajamani U Pannell LK Boyd MR Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum Biochem Biophys Res Commun 1997, 238:223-228. 10.1006/ bbrc.1997.7203 9299483
40. Dey B Lerner DL Lusso P Boyd MR Elder JH Berger EA Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses J Virol 2000, 74:4562-4569. 10.1128/ JVI.74.10.4562-4569.2000 111976 10775592
41. Esser MT Mori T Mondor I Sattentau QJ Dey B Berger EA Boyd MR Lifson JD Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120 J Virol 1999, 73:4360-4371. 104217 10196334
42. Au TK Lam TL Ng TB Fong WP Wan DC A comparison of HIV-1 integrase inhibition by aqueous and methanol extracts of Chinese medicinal herbs Life Sci 2001, 68:1687-1694. 10.1016/S0024-3205(01)00945-6 11263681
43. Del Beccaro MA Mendelman PM Inglis AF Richardson MA Duncan NO Clausen CR Stull TL Bacteriology of acute otitis media: A new perspective J Pediatr 1992, 120:81-84. 10.1016/S0022-3476(05)80605-5 1731029
44. Liu J The use of herbal medicines in early drug development for the treatment of HIV infections and AIDS Expert Opin Investig Drugs 2007, 16:1355-1364. 10.1517/13543784.16.9.1355 17714022
45. Liu S Jiang S Wu Z Lv L Zhang J Zhu Z Wu S Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte Life Sci 2002, 71:1779-1791. 10.1016/S0024-3205(02)01939-2 12151056
46. Tang X Chen H Zhang X Quan K Sun M Screening anti-HIV Chinese materia medica with HIV and equine infectious anemic virus reverse transcriptase J Tradit Chin Med 1994, 14:10-13. 7515133
47. Wu JA Attele AS Zhang L Yuan CS Anti-HIV activity of medicinal herbs: usage and potential development Am J Chin Med 2001, 29:69-81. 10.1142/ S0192415X01000083 11321482